Cornerstone Capital Management Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-11,954	Closed	-$751K	–	1379
2016 Q1	$751K	Sell	11,954 -4,422	-27%	-$294K	0.01%	960
2015 Q4	$1.54M	Sell	16,376 -6,575	-29%	-$610K	0.01%	799
2015 Q3	$1.84M	Buy	22,951 +20,668	+905%	+$2.3M	0.02%	743
2015 Q2	$274K	Sell	2,283 -33,405	-94%	-$3.99M	﹤0.01%	1137
2015 Q1	$3.73M	Buy	35,688 +24,150	+209%	+$2.45M	0.03%	516
2014 Q4	$1.12M	Buy	+11,538	New	+$1.07M	0.01%	862

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Cornerstone Capital Management Holdings's ALNY Position: Q2 2016 in Review

Cornerstone Capital Management Holdings sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2016, closing a stake of 11,954 shares — an estimated $751K sold.

Cornerstone Capital Management Holdings first reported a position in ALNY in Q4 2014 and held it in 6 quarters. The position peaked at $3.73M in Q1 2015. 249 funds tracked by Wall St. Rank hold ALNY as of Q2 2016.

Cornerstone Capital Management Holdings reported no remaining Alnylam Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 11,954 Alnylam Pharmaceuticals shares in Q2 2016, an estimated $751K.
Cornerstone Capital Management Holdings first reported a position in Alnylam Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Cornerstone Capital Management Holdings's Alnylam Pharmaceuticals position peaked at $3.73M in Q1 2015.
249 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.